Renal effects and nephroprotection induced by SGLT2 inhibitor Empagliflozin in patients with Diabetes Mellitus: a literature review

• Main Authors: Luis E. Morales-Buenrostro, Sonia Citlali Juárez-Comboni, Alma Nelly Rodríguez Alcocer
• Format: Article
• Language: Spanish
• Published: Asociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires 2017-01-01
• Series: Revista de Nefrología, Diálisis y Trasplante
• Subjects: enfermedad renal crónica; diabetes mellitus; nefroprotección; empagliflozina
• Online Access: http://www.revistarenal.org.ar/index.php/rndt/article/view/89

Chronic kidney disease is a frequent comorbidity in patients with diabetes mellitus (DM) and it increases their cardiovascular risk; chronic hyperglycemia in patients with DM leads to direct and indirect disorders in kidney's structure and function, and it is the principal risk factor for the development of diabetic nephropathy and end-stage renal disease. In the current review, results of studies are exposed in which high tolerability of empagliflozin is exposed in diabetic patients with kidney disease. Empagliflozin by inhibiting SGLT2 provides a novel therapy with benefic effects, not only in glycemic control, but it also has cardiovascular and renal benefits, which they have been demonstrated in the EMPA-REG OUTCOME trial, and continue in evaluation in other studies.